Is Ixazomib/Enleri a chemotherapy drug or a targeted drug?

Ixazomib/Enleri (Ixazomib) is a targeted therapy drug, an oral proteasome inhibitor (proteasome inhibitor ), mainly used to treat multiple myeloma (MM). Compared with traditional chemotherapy drugs, ixazomib has a more specific mechanism of action and can interfere with the survival and proliferation of cancer cells by inhibiting intracellular protein degradation pathways.

The mechanism of action of ixazomib interferes with the survival of cancer cells by reversibly inhibiting the function of the proteasome. In normal cells, the proteasome is responsible for breaking down unwanted or damaged proteins, acting like an intracellular recycling center. Through this process, cells are able to maintain a good protein balance without allowing harmful proteins to accumulate within the cells. However, ixazomib works by inhibiting this process, causing damaged and unnecessary proteins to accumulate within cancer cells, leading to their death.

In the treatment of multiple myeloma, ixazomib is often used in combination with other drugs such as lenalidomide and dexamethasone. This combination therapy can enhance the therapeutic effect and improve the patient's treatment response rate. Research shows that combination treatments can target myeloma cells more effectively and reduce the development of drug resistance than single-drug treatments.

As an oral medication, ixazomib offers significant convenience. Patients can take it orally in capsule form without the need for intravenous injection, which not only makes medication easier, but also reduces the risk of infection that may be caused by intravenous administration. At the same time, the oral approach provides patients with greater flexibility in their daily lives and improves treatment compliance. In clinical application, the side effects of ixazomib are usually mild, but possible thrombocytopenia, diarrhea, fatigue, etc. still need to be monitored.